Technical Analysis for CELG - Celgene Corporation

Grade Last Price % Change $ Change
grade B $119.44 -1.42% -1.72
CELG closed down 1.42 percent on Tuesday, February 21, 2017, on 1.13 times normal volume.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical CELG trend table...

Date Alert Name Type % Chg
Feb 21 Stochastic Sell Signal Bearish 0.00%
Feb 17 180 Bullish Setup Bullish Swing Setup -1.42%
Feb 15 Stochastic Reached Overbought Other -0.85%
Feb 15 Expansion Pivot Buy Setup Bullish Swing Setup -0.85%
Feb 14 50 DMA Support Bullish 2.07%
Feb 13 Crossed Above 50 DMA Bullish 2.59%
Feb 13 NR7 Range Contraction 2.59%
Feb 13 Bollinger Band Squeeze Range Contraction 2.59%
Feb 10 Fell Below 50 DMA Bearish 3.31%
Feb 10 180 Bearish Setup Bearish Swing Setup 3.31%

Older signals for CELG ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.

Celgene Corporation discovers, develops, and commercializes therapies for cancer and immune-inflammatory related diseases in the United States and Europe. Its commercial stage products include REVLIMID, a drug to treat multiple myeloma and transfusion-dependent anemia; VIDAZA, a nucleoside analog to treat intermediate-2 and myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML); ABRAXANE, a chemotherapy treatment option for metastatic breast cancer; and THALOMID for multiple myeloma and the cutaneous manifestations of erythema nodosum leprosum. The company’s commercial stage products also comprise ISTODAX to treat cutaneous T-cell lymphoma; POMALYST for the multiple myeloma and myelofibrosis treatment; and FOCALIN, FOCALIN XR, and RITALIN LA products. Its pre clinical and clinical stage products consist of CC-11050, an anti-inflammatory compound; CC-220, an anti-inflammatory product; cellular therapies, such as PDA-001 and PDA-002; CC-486 that is in Phase III trials to treat MDS and AML, as well as in a Phase I trials for solid tumor indications; and sotatercept and ACE-536, which are in Phase II trials to treat anemia. The company’s pre clinical and clinical stage products also include CC-223, a dual TORK inhibitor; CC-292, a BTK inhibitor; CC-115, a dual TORK/DNA PK inhibitor; CC-122, a pleiotropic pathway modulator; and EPZ-5676, a DOT1L inhibitor. It has strategic collaborations with bluebird bio, Inc.; FORMA Therapeutics Holdings; Concert Pharmaceuticals, Inc.; Array BioPharma, Inc.; and Acetylon Pharmaceuticals, Inc., as well as a strategic alliance with MorphoSys AG. The company was founded in 1980 and is headquartered in Summit, New Jersey.
Is CELG a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 127.0
52 Week Low 94.39
Average Volume 4,112,541
200-Day Moving Average 109.38
50-Day Moving Average 116.37
20-Day Moving Average 116.14
10-Day Moving Average 117.71
Average True Range 2.39
ADX 14.1
+DI 24.81
-DI: 13.37
Chandelier Exit (Long, 3 ATRs) 115.05
Chandelier Exit (Short, 3 ATRs) 118.23
Upper Bollinger Band 121.04
Lower Bollinger Band 111.24
Percent B (%b) 0.84
Bandwidth 0.084381